11/13/2012

AstraZeneca has teamed up with Foundation Medicine to identify genetic mutations in cancer-related tumor genes that may help predict a person's response or resistance to targeted treatments. Under terms of the deal, Foundation will get right of first negotiation to develop diagnostic tests. The deal will allow AstraZeneca to "identify tumor-specific defects and alterations that can be used for patient segmentation," said Susan Galbraith, vice president and head of AstraZeneca's Oncology Innovative Medicines Unit.

Related Summaries